Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Yang YS, Hu WP, Ni PZ, Wang WP, Yuan Y, Chen LQ. Esophageal luminal stenosis is an independent prognostic factor in esophageal squamous cell carcinoma. Oncotarget. 2017;8(26):43397–43405. doi:10.18632/oncotarget.1476228118615
   PubMedGoogle Scholar
• Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15(1):69–79. doi:10.1245/s10434-007-9596-017896140
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027. doi:10.1200/JCO.2005.06.08115585754
   PubMed Web of Science ®Google Scholar
• Luz C, Noguti J, Araújo L, et al. Expression of VEGF and Cox-2 in patients with esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2018;19(1):171–177. doi:10.22034/APJCP.2018.19.1.17129373910
   PubMedGoogle Scholar
• Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374–1380. doi:10.1111/j.1349-7006.2011.01939.x21443688
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454. doi:10.1200/JCO.2015.63.599526884585
   PubMed Web of Science ®Google Scholar
• Song Z, Yu X, Lou G, Shi X, Zhang Y. Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther. 2017;10:1821–1825. doi:10.2147/OTT.S11343528367065
   PubMed Web of Science ®Google Scholar
• Hu X, Cao J, Hu W, et al. Multicenter Phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. doi:10.1186/1471-2407-14-82025376790
   PubMed Web of Science ®Google Scholar
• Li F, Liao Z, Zhao J, et al. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017;8(38):64471–64480. doi:10.18632/oncotarget.1629328969086
   PubMedGoogle Scholar
• Jackman AL, Farrugia DC, Gibson W, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer. 1995;31(7–8):1277–1282. doi:10.1016/0959-8049(95)00166-g
   Google Scholar
• Kelly C, Bhuva N, Harrison M, Buckley A, Saunders M. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer. 2013;49(10):2303–2310. doi:10.1016/j.ejca.2013.03.00423583220
   PubMed Web of Science ®Google Scholar
• Planting A, de Jong M, Jansen P, Kerrebijn J, Smith M, Verweij J. Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer. Eur J Cancer. 2005;41(1):93–97. doi:10.1016/j.ejca.2004.09.02215719490
   PubMed Web of Science ®Google Scholar
• van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–6889. doi:10.1200/JCO.20005.14.58916192580
   PubMed Web of Science ®Google Scholar
• Xue S, Chen YX, Qin SK, et al. Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells. Mol Med Rep. 2014;10(4):1927–1934. doi:10.3892/mmr.2014.243825109431
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhang Y, Sun J, Zhan C, Zhao L. Raltitrexed inhibits HepG2 cell proliferation via G0/G1 cell cycle arrest. Oncol Res. 2016;23(5):237–248. doi:10.3727/096504016X1456272537367127098147
   PubMed Web of Science ®Google Scholar
• Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 2006;94(6):785–791. doi:10.1038/sj.bjc.660302616508631
   PubMed Web of Science ®Google Scholar
• Hu L, Sun F, Sun Z, et al. Apatinib enhances the radiosensitivity of the esophageal cancer cell line KYSE-150 by inducing apoptosis and cell cycle redistribution. Oncol Lett. 2019;17(2):1609–1616. doi:10.3892/ol.2018.980330675220
   PubMed Web of Science ®Google Scholar
• Ding WX, Liu S, Ma JX, et al. Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells. Cancer Cell Int. 2019;19:36. doi:10.1186/s12935-019-0752-y30820189
   PubMed Web of Science ®Google Scholar
• Xu WW, Li B, Lam AK, et al. Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy. Oncotarget. 2015;6(3):1790–1805. doi:10.18632/oncotarget.278125595897
   PubMed Web of Science ®Google Scholar
• Li H, Juan L, Xia L, Wang Y, Bao Y, Sun G. Thioridazine sensitizes esophageal carcinoma cell lines to radiotherapy-induced apoptosis in vitro and in vivo. Med Sci Monit. 2016;22:2624–2634. doi:10.12659/MSM.89995027453171
   PubMed Web of Science ®Google Scholar
• Wu J, Yu J, Wang J, et al. Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway. Biomed Pharmacother. 2018;100:176–183. doi:10.1016/j.biopha.2018.01.14029428665
   PubMed Web of Science ®Google Scholar
• Wu J, Wang J, Su Q, et al. Traditional Chinese medicine Astragalus polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis. Onco Targets Ther. 2018;11:2685–2698. doi:10.2147/OTT.S15712929785118
   PubMed Web of Science ®Google Scholar
• Ma Y, Yu J, Li Q, Su Q, Cao B. Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy. Biosci Biotechnol Biochem. 2020;84(4):743–756. doi:10.1080/09168451.2019.170978931889475
   PubMed Web of Science ®Google Scholar
• Pan W, Yang J, Wei J, et al. Functional BCL-2 regulatory genetic variants contribute to susceptibility of esophageal squamous cell carcinoma. Sci Rep. 2015;5:11833. doi:10.1038/srep1183326132559
   PubMed Web of Science ®Google Scholar
• Yang L, Song X, Zhu J, et al. Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. Int J Oncol. 2017;51(1):378–388. doi:10.3892/ijo.2017.401528534990
   PubMed Web of Science ®Google Scholar
• Frezzetti D, Gallo M, Roma C, et al. Vascular endothelial growth factor a regulates the secretion of different angiogenic factors in lung cancer cells. J Cell Physiol. 2016;231(7):1514–1521. doi:10.1002/jcp.2524326542886
   PubMed Web of Science ®Google Scholar
• Qiu H, Li J, Liu Q, Tang M, Wang Y. Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel. Cell Cycle (Georgetown, Tex). 2018;17(10):1235–1244. doi:10.1080/15384101.2018.1471315
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Kirchmair A, Sato A, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol. 2020;21(10):1160–1171. doi:10.1038/s41590-020-0751-032747819
   PubMed Web of Science ®Google Scholar
• Wei L, Chen Z, Cheng N, et al. MicroRNA-126 inhibit viability of colorectal cancer cell by repressing mTOR induced apoptosis and autophagy. Onco Targets Ther. 2020;13:2459–2468. doi:10.2147/OTT.S23834832273718
   PubMed Web of Science ®Google Scholar
• Yang L, Zhu H, Luo P, Chen S, Xu Y, Wang C. Apatinib mesylate tablet in the treatment of advanced malignant melanoma. Onco Targets Ther. 2018;11:5333–5338. doi:10.2147/OTT.S17550730214239
   PubMed Web of Science ®Google Scholar
• Yu WC, Zhang KZ, Chen SG, Liu WF. Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: a prospective observation study. Medicine (Baltimore). 2018;97(3):e9704. doi:10.1097/MD.000000000000970429505026
   PubMed Web of Science ®Google Scholar
• Gou M, Si H, Zhang Y, et al. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Sci Rep. 2018;8(1):4602. doi:10.1038/s41598-018-22302-z29545575
   PubMedGoogle Scholar
• Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75–82. doi:10.1007/s00432-007-0250-917636329
   PubMed Web of Science ®Google Scholar
• Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191–202. doi:10.1517/1474033090273396119309247
   PubMed Web of Science ®Google Scholar
• Candido S, Abrams SL, Steelman LS, et al. Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy. Biochim Biophys Acta. 2016;1863(3):438–448. doi:10.1016/j.bbamcr.2015.08.01026278055
   PubMed Web of Science ®Google Scholar
• Barillari G. The impact of matrix metalloproteinase-9 on the sequential steps of the metastatic process. Int J Mol Sci. 2020;21(12):4526. doi:10.3390/ijms21124526
   PubMed Web of Science ®Google Scholar
• Ewald F, Nörz D, Grottke A, et al. Vertical targeting of AKT and mTOR as well as dual targeting of AKT and MEK signaling is synergistic in hepatocellular carcinoma. J Cancer. 2015;6(12):1195–1205. doi:10.7150/jca.1245226535060
   PubMed Web of Science ®Google Scholar
• Adlung L, Kar S, Wagner MC, et al. Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. Mol Syst Biol. 2017;13(1):904. doi:10.15252/msb.2016725828123004
   PubMed Web of Science ®Google Scholar
• Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314–341. doi:10.1016/j.ejmech.2016.01.01226807863
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–1284. doi:10.1016/j.bbamcr.2006.10.00117126425
   PubMed Web of Science ®Google Scholar
• Liang LJ, Wen YX, Xia YY, Wang L, Fei JY, Jiang XD. Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report. Onco Targets Ther. 2018;11:5821–5826. doi:10.2147/OTT.S17442930271164
   PubMed Web of Science ®Google Scholar
• Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther. 2017;10:3965–3969. doi:10.2147/OTT.S13275628860804
   PubMed Web of Science ®Google Scholar